MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202514062317 A) filed by University Of Reading, Reading, U.K., on June 30, 2025, for 'combination therapy for envenomation.'
Inventor(s) include Vaiyapuri, Sakthivel; Patel, Ketan; and Almeida, Jose Rafael De.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a combination composition or kit for the prevention or amelioration of the effects of envenomation, such as that caused by snake venom. The composition comprises a tyrosine kinase inhibitor in combination with at least one of a phospholipase A2 (PLA2) inhibitor and a matrix metalloprotease (MMP) inhibitor. In preferred embodiments, the tyrosine kinase inhibitor is nilotinib, the PLA2 inhibitor is varespladib, and the MMP inhibitor is marimastat. The combination may optionally be administered with antivenom and formulated as a pharmaceutical composition for therapeutic use."
Disclaimer: Curated by HT Syndication.
